top of page
Nervovita tVNS Vivo Cardiangel vagus uyarımı

Changing the World
Changing the Lives

Discover a non-invasive, medication-free therapy with low side effects for treating brain diseases. Take an active role in your health journey and be part of your success story

patient using tVNS
ce0123 CE approval

In the treatment of brain diseases
tVNS® VAGUS NEUROMODULATION DEVICES

tVNS® is the world pioneer of non-surgical vagus nerve stimulation treatment, developed in Germany as a result of over 20 years of scientific research. It is the only ear-based vagus nerve stimulation device globally approved for medical use, proven in clinical trials in many countries and available in over 50 countries.

In the treatment of Chronic and Acute Pain
VIVO® NEUROMODULATION DEVICES

VIVO® minimally invasive ear vagus nerve stimulation devices set a new standard in pain relief. This groundbreaking technology, which is easy to use and has low side effects, can be customized for individual needs, effectively and sustainably combating chronic pain.

In 2024, following approval by the Ministry of Health, it will be available in Turkey.

Patient using in vivo aVNS
CE_0483 CE approval
CardiAngel heart shock device
CE approval

In Sudden Cardiac Arrest
CardiAngel® PORTABLE HEART SHOCK DEVICES

CardiAngel, one of the world's best defibrillation technologies, provides a second chance at life by enabling the heart to be restarted during the critical time before the ambulance arrives in cases of sudden cardiac arrest.

Digital healthcare services

tVNS® CARE THERAPY FOLLOW-UP SERVICES

With digital health technologies and patient monitoring services that eliminate boundaries and limits, your treatment is under the supervision of our expert healthcare professionals, utilizing tailored treatment protocols specific to the disease and the patient's unique needs.

Using tVNS App
global sales

Medical Device Global Channel Management
Regulation and Sales Management Services

With 22 years of international market and channel development experience across 6 continents and offices in 5 countries, we become your global sales management solution partner for medical devices throughout all product development processes. From R&D to FDA-CE approval services, distributor management to global brand management, we stand by your side with a strong team of leading professionals in their fields.

After experiencing cardiac arrest post-birth, my patient was hypoxic with a Glasgow Coma Scale score between 4-5. We started using tVNS in the 7th month of the coma. By the 5th month of treatment, the patient began to speak. At the end of 12 months, they were discharged from the hospital with a full score of 15.

Prof. Dr. Halil ÖZCAN, Atatürk University

bottom of page